CN102089306A - 可用于治疗的取代的氢化吡啶并[3,2,1-ij]喹啉化合物 - Google Patents

可用于治疗的取代的氢化吡啶并[3,2,1-ij]喹啉化合物 Download PDF

Info

Publication number
CN102089306A
CN102089306A CN2009801266353A CN200980126635A CN102089306A CN 102089306 A CN102089306 A CN 102089306A CN 2009801266353 A CN2009801266353 A CN 2009801266353A CN 200980126635 A CN200980126635 A CN 200980126635A CN 102089306 A CN102089306 A CN 102089306A
Authority
CN
China
Prior art keywords
hydroxyalkyl
aminocarbonyl
group
hydrogen
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801266353A
Other languages
English (en)
Chinese (zh)
Inventor
S·C·辛哈
S·巴特
周健雄
R·L·比尔德
J·E·唐奈罗
M·E·加斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN102089306A publication Critical patent/CN102089306A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2009801266353A 2008-05-08 2009-05-07 可用于治疗的取代的氢化吡啶并[3,2,1-ij]喹啉化合物 Pending CN102089306A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5153308P 2008-05-08 2008-05-08
US61/051,533 2008-05-08
US12/433,978 US20090281322A1 (en) 2008-05-08 2009-05-01 THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS
US12/433,978 2009-05-01
PCT/US2009/043149 WO2009137681A1 (en) 2008-05-08 2009-05-07 Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds

Publications (1)

Publication Number Publication Date
CN102089306A true CN102089306A (zh) 2011-06-08

Family

ID=40863539

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801266353A Pending CN102089306A (zh) 2008-05-08 2009-05-07 可用于治疗的取代的氢化吡啶并[3,2,1-ij]喹啉化合物

Country Status (10)

Country Link
US (1) US20090281322A1 (enExample)
EP (1) EP2294069B1 (enExample)
JP (1) JP5432246B2 (enExample)
CN (1) CN102089306A (enExample)
AU (1) AU2009244199B2 (enExample)
BR (1) BRPI0912534A2 (enExample)
CA (1) CA2723798A1 (enExample)
IL (1) IL209200A0 (enExample)
RU (1) RU2010149312A (enExample)
WO (1) WO2009137681A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107369775A (zh) * 2017-07-13 2017-11-21 长春海谱润斯科技有限公司 一种有机电致发光材料及其有机发光器件
CN107492597A (zh) * 2017-08-10 2017-12-19 长春海谱润斯科技有限公司 一种顶发射有机发光器件
CN109153655A (zh) * 2016-04-26 2019-01-04 高丽大学校产学协力团 用于预防或治疗心血管疾病的新型n-酰基脲衍生物和包含其的组合物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013024657A2 (pt) * 2011-03-25 2016-12-20 Allergan Inc antagonistas da s1p como hipotensivos oculares adjuntos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1513522A2 (en) * 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
EP1546143A1 (en) * 2002-09-17 2005-06-29 Warner-Lambert Company LLC Heterocyclic substituted piperazines for the treatment of schizophrenia
US20040131648A1 (en) * 2002-10-24 2004-07-08 The Procter & Gamble Company Nuclear hormone receptor compounds, products and methods employing same
US20040167185A1 (en) * 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associated with an Edg-3 receptor
US8629147B2 (en) * 2005-11-03 2014-01-14 Chembridge Corporation Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
WO2007112322A2 (en) * 2006-03-28 2007-10-04 Allergan, Inc. Indole compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109153655A (zh) * 2016-04-26 2019-01-04 高丽大学校产学协力团 用于预防或治疗心血管疾病的新型n-酰基脲衍生物和包含其的组合物
CN109153655B (zh) * 2016-04-26 2022-09-30 高丽大学校产学协力团 用于预防或治疗心血管疾病的新型n-酰基脲衍生物和包含其的组合物
CN107369775A (zh) * 2017-07-13 2017-11-21 长春海谱润斯科技有限公司 一种有机电致发光材料及其有机发光器件
CN107492597A (zh) * 2017-08-10 2017-12-19 长春海谱润斯科技有限公司 一种顶发射有机发光器件
CN107492597B (zh) * 2017-08-10 2018-11-27 长春海谱润斯科技有限公司 一种顶发射有机发光器件

Also Published As

Publication number Publication date
US20090281322A1 (en) 2009-11-12
CA2723798A1 (en) 2009-11-12
RU2010149312A (ru) 2012-06-20
IL209200A0 (en) 2011-01-31
AU2009244199A1 (en) 2011-10-06
JP5432246B2 (ja) 2014-03-05
EP2294069B1 (en) 2015-09-02
WO2009137681A1 (en) 2009-11-12
JP2011527286A (ja) 2011-10-27
EP2294069A1 (en) 2011-03-16
BRPI0912534A2 (pt) 2015-10-13
AU2009244199B2 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
AU2018312326B2 (en) Heterocyclic compound and use thereof
RU2089549C1 (ru) Производные гетероциклилметилхромана в виде смеси изомеров или отдельных изомеров или их соли
CN112236423B (zh) 哌啶基-3-(芳氧基)丙酰胺和丙酸酯
KR20170066628A (ko) Ror-감마의 디히드로피롤로피리딘 억제제
KR20190005838A (ko) 이중 lsd1/hdac 억제제로서 사이클로프로필-아마이드 화합물
JP2009524689A (ja) 化合物
TW202216677A (zh) 作為ａｌｋ５抑制劑之嗒基胺基衍生物
JP2009507795A (ja) 化合物
CN102089306A (zh) 可用于治疗的取代的氢化吡啶并[3,2,1-ij]喹啉化合物
WO2010064735A1 (en) Quinolone compound and pharmaceutical composition
JP7739327B2 (ja) Ｓｓｔｒ４アゴニストとしてのｎ－ヘテロアリールアルキル－２－（ヘテロシクリル及びヘテロシクリルメチル）アセトアミド誘導体
US20040052822A1 (en) Dihydropyrazolopyridine compounds and pharmaceutical use thereof
KR20030076650A (ko) 디하이드로피라졸로피리딘 화합물 및 그의 약학적 용도
CN101481323A (zh) 苯并环庚烯类衍生物、其制备方法及医药用途
US8431702B2 (en) Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds
JP2025525078A (ja) 新規なスルホンアミドならびに神経保護剤および／または神経修復剤としてのそれらの使用
US5147873A (en) Amino-substituted bridged azabicyclic quinolone carboxylic acids and esters
EP0356193B1 (en) Amino-substituted bridged azabicyclic quinolone carboxylic acids and esters
WO2025155789A1 (en) Indane-, indene-, azaindane-, and azaindene-amines as activators of serotonin receptors
JP2025124692A (ja) 神経障害の治療に使用するための化合物
TW202448900A (zh) Irak4降解劑及其用途
JP2025179155A (ja) Ｓｓｔｒ４アゴニストとしてのｎ－ヘテロアリールアルキル－２－（ヘテロシクリル及びヘテロシクリルメチル）アセトアミド誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110608